"For the millions of people who suffer from atopic dermatitis (AD), or eczema, ENS-002 represents a potential paradigm shift in care." Current treatments like steroids and immunosuppressants may come ...

Eczema is relatively common, affecting 20 percent of children and 10 percent of adults around the world (1). If you are one of the many who experiences eczema, you know the symptoms, which can include ...

Therefore, even individuals without childhood eczema may experience it later in life. Dr Grant has debunked the common ...

An Auckland-based artist living with debilitating symptoms of topical steroid withdrawal (TSW) believes his dermatologists ...

For many, fall is their favourite time of year. The bugs are gone, the leaves are turning colours and the holidays are on the ...

Albertans living with an autoimmune disease that causes the discoloration and depigmentation of skin now have a new sense of ...

There are lots of misconceptions around eczema, from poor hygiene to the skin condition disappearing on its own - there is a ...

Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...

Its safety data was in line with findings from earlier studies, while the proportion of patients who had experienced treatment-emergent adverse events was similar between the icotrokinra and placebo ...